Clene (CLNN) Competitors $5.88 -0.17 (-2.81%) Closing price 04:00 PM EasternExtended Trading$6.03 +0.15 (+2.48%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN vs. VYGR, HRTX, PRQR, SXTC, PBYI, AVTE, OGI, VOR, SGMT, and CRGXShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Voyager Therapeutics (VYGR), Heron Therapeutics (HRTX), ProQR Therapeutics (PRQR), China SXT Pharmaceuticals (SXTC), Puma Biotechnology (PBYI), Aerovate Therapeutics (AVTE), Organigram Global (OGI), Vor Biopharma (VOR), Sagimet Biosciences (SGMT), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. Clene vs. Its Competitors Voyager Therapeutics Heron Therapeutics ProQR Therapeutics China SXT Pharmaceuticals Puma Biotechnology Aerovate Therapeutics Organigram Global Vor Biopharma Sagimet Biosciences CARGO Therapeutics Voyager Therapeutics (NASDAQ:VYGR) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Do analysts rate VYGR or CLNN? Voyager Therapeutics currently has a consensus target price of $13.25, suggesting a potential upside of 223.89%. Clene has a consensus target price of $32.60, suggesting a potential upside of 454.42%. Given Clene's higher possible upside, analysts plainly believe Clene is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, VYGR or CLNN? Clene has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$80M2.84-$65M-$1.85-2.21Clene$340K174.15-$39.40M-$3.76-1.56 Does the media prefer VYGR or CLNN? In the previous week, Clene had 5 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Clene and 3 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.60 beat Clene's score of 0.59 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Clene 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in VYGR or CLNN? 48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 6.4% of Voyager Therapeutics shares are held by company insiders. Comparatively, 35.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, VYGR or CLNN? Voyager Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Is VYGR or CLNN more profitable? Voyager Therapeutics has a net margin of -253.49% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat Voyager Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-253.49% -37.65% -28.89% Clene -10,386.36%N/A -125.49% SummaryVoyager Therapeutics beats Clene on 10 of the 17 factors compared between the two stocks. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricCleneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.92M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.77%4.64%P/E Ratio-1.5620.6375.7726.11Price / Sales174.15442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book-5.559.6212.876.30Net Income-$39.40M-$52.73M$3.29B$271.03M7 Day Performance-6.96%0.64%-0.26%-0.15%1 Month Performance10.32%6.31%3.84%6.41%1 Year Performance26.18%18.97%68.35%28.81% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene3.1743 of 5 stars$5.88-2.8%$32.60+454.4%+37.2%$60.92M$340K-1.56100News CoverageAnalyst ForecastVYGRVoyager Therapeutics4.1451 of 5 stars$4.21+0.7%$13.25+214.7%-29.6%$231.86M$80M-2.28100News CoveragePositive NewsHRTXHeron Therapeutics4.07 of 5 stars$1.24-1.6%$4.50+262.9%-36.2%$230.98M$144.29M-62.00300Positive NewsPRQRProQR Therapeutics2.4554 of 5 stars$1.99-9.1%$8.00+302.0%+25.0%$230.41M$20.46M-4.33180Positive NewsSXTCChina SXT Pharmaceuticals1.2526 of 5 stars$1.86-6.1%N/A-69.6%$229.74M$1.74M0.0090Positive NewsGap UpPBYIPuma Biotechnology4.0064 of 5 stars$4.64+3.8%$7.00+50.9%+85.1%$225.16M$230.50M4.73200Positive NewsAVTEAerovate TherapeuticsN/A$7.70-0.8%N/A-88.9%$223.18MN/A-2.5820Positive NewsHigh Trading VolumeOGIOrganigram Global1.2951 of 5 stars$1.71+3.0%N/A+0.6%$222.52M$117.47M34.21860Positive NewsVORVor BiopharmaN/A$1.60-8.0%N/AN/A$220.43MN/A0.00140News CoverageStock SplitGap DownSGMTSagimet Biosciences3.4325 of 5 stars$6.36-5.9%$25.67+303.6%+154.5%$219.85M$2M-3.488CRGXCARGO Therapeutics1.5558 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116 Related Companies and Tools Related Companies VYGR Competitors HRTX Competitors PRQR Competitors SXTC Competitors PBYI Competitors AVTE Competitors OGI Competitors VOR Competitors SGMT Competitors CRGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLNN) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
